Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas
  
Novo Nordisk's amycretin demonstrates weight loss, HbA1c improvement in type 2 diabetes trial (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business